

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

*(formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. 杭州九源基因工程股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)*

(Stock code: 2566)

CHANGE OF COMPANY NAME

References are made to (i) the announcement of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (the “**Company**”) dated February 12, 2025, (ii) the circular of the Company dated February 12, 2025, (iii) the poll results announcement of the Company dated March 5, 2025 in relation to, among other things, the proposed change of the Company name (the “**Change of Company Name**”), and (iv) the announcement of the Company dated April 2, 2025 in relation to the Change of Company Name (the “**Announcements and Circular**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements and Circular.

REGISTRATION OF CHANGE OF COMPANY NAME IN HONG KONG

The Company obtained the Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company issued by the Registrar of Companies in Hong Kong on April 17, 2025, which confirmed that the English name of the Company registered in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the laws of Hong Kong) was changed from “Hangzhou Jiuyuan Gene Engineering Co., Ltd.” to “Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.” and the Chinese name was changed from “杭州九源基因工程股份有限公司” to “杭州九源基因生物醫藥股份有限公司”.

EFFECT OF THE CHANGE OF COMPANY NAME

The Change of Company Name will not affect any rights of the Shareholders or the Company's daily business operation and its financial position (including the share price of the Company and the investors will not be misled).

All existing certificates of securities in issue bearing the former name of the Company will continue to be evidence of the title and valid for trading, settlement, registration and delivery purposes. Share certificates of the Company have been issued on April 15, 2025 in the new name of the Company in any subsequent issue of Shares and the Shares will be traded on the main board of the Stock Exchange under the new name. There will be no arrangement for the exchange of existing share certificates for new share certificates bearing the new name of the Company.

After the Change of Company Name, the Company's stock code, the Chinese stock short name (九源基因) and the English stock short name (JIUYUAN GENE) remain unchanged.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, May 11, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.